ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1200

Plasma Levels of Pattern Recognition Molecules of the Lectin Pathway Are Altered in SLE Patients

Anne Troldborg1,2, Steffen Thiel3, Magdalena Janina Laska3, Bent Deleuran4,5, Jens Christian Jensenius3 and Kristian Stengaard-Pedersen2,6, 1clinical medicine, Aarhus University, Aarhus, Denmark, 2Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Biomedicine, Aarhus University, Aarhus, Denmark, 4Department of Biomedicine, Aarhus University, Aarhus, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Clinical medicine, Aarhus University, Aarhus, Denmark

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: complement, innate immunity and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Signaling Mechanisms

Session Type: Abstract Submissions (ACR)

Background/Purpose

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease where the Complement System plays a key role in the pathogenesis. The objective of this pilot study was to measure the levels of the pattern recognition molecules of the Lectin Pathway: mannan binding lectin (MBL), collectin-L1 (CL-L1), and the three ficolins in plasma of patients with SLE and compare the plasma levels to a group of age and gender matched healthy controls. Further, we analyzed for associations between the plasma levels and SLE disease activity score and characteristic SLE manifestations.

Methods

Plasma was obtained from a cross-sectional cohort of 58 SLE patients. We collected prospectively demographic and clinical data including ACR classification criteria and SLE disease activity index score (SLEDAI). For comparison, blood samples were collected from 65 age and gender matched healthy blood donors. Plasma levels of MBL, CL-L1, M-ficolin (Ficolin-1) and H-ficolin (Ficolin-3) were measured using Time Resolved Immuno-Flourometric Assay (TRIFMA) developed at our own lab. Plasma levels of L-ficolin (Ficolin-2) were measured by ELISA (Hycult Biotech¨, the Netherlands). Mann-Whitney test were used for comparison of plasma levels of the proteins in patients and controls and Spearman correlation analysis was used for correlation analysis. p values < 0.05 were considered statistically significant.

Results

RESULTS

SLE Patients (n=58)

Mean plasma conc. ng/ml (SD)

Healthy Controls (n=65)

Mean plasma conc. ng/ml (SD)

Difference between means ng/ml (SD)

Mann-Whitney            P value

MBL

1003(±821)

1137(±1157)

219,5 ± 183,5

0,5204

CL-L1

771(±145)

937(±191)

165,5 ± 30,84

< 0,0001

M-ficolin

356(±231)

564(±266)

214,1 ± 46,96

< 0,0001

L-ficolin

2649(±1031)

2554(±998)

94,97 (± 192,5)

0,6116

H-ficolin

23998 (±10397)

16387(±4927)

7611 (± 1450)

<0,0001

Mean plasma levels of CL-L1 and M-ficolin were significantly lower and H-ficolin significantly higher in patients with SLE compared to healthy controls (p<0.0001). A statistical significant difference between plasma levels of H-ficolin in SLE patients with lymphopenia compared to the non-lymphopenic patients was found (p=0.0434). A relatively higher level of CL-L1 in the subgroup of SLE patients with discoid rash was statistically significant (p=0.0364). Otherwise, analysis showed no statistically significant association between characteristic disease manifestations or SLEDAI score on one side and plasma level of MBL, CL-L1, M-ficolin, L-ficolin and H-ficolin on the other hand.

Conclusion

The plasma concentrations of several of the pattern recognition molecules of the Lectin Pathway were significantly altered in a cross-sectional co-hort of SLE-patients showing low levels of CL-L1 and M-ficolin and high levels of H-ficolin. In the subgroup of patients with lymphopenia, this manifestation was associated with a high level of H-ficolin. The association with a key element of the clinical picture, lymphopenia, may indicate a pathogenic role of Ficolin-3 in SLE.

A limitation of the study is small SLE subgroups.


Disclosure:

A. Troldborg,
None;

S. Thiel,
None;

M. J. Laska,
None;

B. Deleuran,
None;

J. C. Jensenius,
None;

K. Stengaard-Pedersen,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-levels-of-pattern-recognition-molecules-of-the-lectin-pathway-are-altered-in-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology